Needham Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $282

Benzinga Newsdesk www.benzinga.com Positive 80.8%

Neg 0% Neu 0% Pos 80.8%

Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $255 to $282.